Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pontine Tumors Clear all
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine Glioma, Osteosarcoma, Neuroblastoma, DIPG Brain Tumor
Interventions
Eflornithine (DFMO), AMXT 1501 Dicaprate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain Cancer
Interventions
cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Brain Tumor
Interventions
Exablate, Doxorubicin
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
vandetanib and dasatinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Months to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma
Interventions
Depatuxizumab mafodotin, Temozolomide, Lomustine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Up to 99 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced May 22, 2026, 12:14 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
Interventions
Temozolomide, Bevacizumab, Irinotecan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 30 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, High-grade Glioma
Interventions
Crizotinib, Dasatinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
adjuvant therapy, pegylated interferon alfa
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions
Nivolumab, NKTR-214
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Valproic acid, Bevacizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm
Interventions
SC-CAR4BRAIN
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Larotrectinib, Larotrectinib surgical
Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Diffuse Pontine Gliomas
Interventions
nimotuzumab (anti EGFR humanized monoclonal antibody)
Biological
Lead sponsor
YM BioSciences
Industry
Eligibility
3 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2011 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioma, High Grade Glioma, Pontine Tumors
Interventions
Dasatinib, Everolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
1 Year to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced May 22, 2026, 12:14 AM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Gemcitabine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Brain Cancer, Brain Stem Tumors, Pontine Tumors
Interventions
Rindopepimut
Biological
Lead sponsor
Paul Graham Fisher
Other
Eligibility
3 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions
Dordaviprone (ONC201)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced May 22, 2026, 12:14 AM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
Interventions
OKN-007
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
13 Months to 18 Years
U.S. locations
9
States / cities
Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced May 22, 2026, 12:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Interventions
9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
Up to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
9
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced May 22, 2026, 12:14 AM EDT